Steven L. Flamm
Northwestern University
Internal medicineGenotypeSurgeryViral loadVirologyRetrospective cohort studyIntensive care medicineImmunologyHepatitis C virusHepatitis CLiver diseaseCirrhosisSofosbuvirLiver transplantationRibavirinHepatic encephalopathyRegimenIn patientChronic hepatitisMedicineGastroenterology
190Publications
44H-index
10.8kCitations
Publications 194
Newest
#1Sonalie PatelH-Index: 1
#2Michelle T. Martin (UIUC: University of Illinois at Urbana–Champaign)H-Index: 8
Last. Steven L. Flamm (NU: Northwestern University)H-Index: 44
view all 3 authors...
Recently, we read with interest the publication by Berkan-Kawinska and colleagues which compared real world hepatitis C virus (HCV) treatment in patients with decompensated cirrhosis and compensated cirrhosis. Authors noted that use of treatment regimens including a protease inhibitor did not increase the risk of hepatic decompensation.1 We would like to present additional data, particularly regarding the use of sofosbuvir/velpatasvir/voxilaprevir as a salvage therapy in this difficult-to-cure p...
Source
#1Parita V Patel (NU: Northwestern University)
#2Steven L. Flamm (NU: Northwestern University)H-Index: 44
Source
#1Robert S. Rahimi (Baylor University Medical Center)H-Index: 17
#2Kimberly A. Brown (HFH: Henry Ford Hospital)H-Index: 21
Last. Robert S. Brown (Cornell University)H-Index: 154
view all 4 authors...
Overt hepatic encephalopathy is a generally reversible neurologic complication of cirrhosis. Overt hepatic encephalopathy has been associated with poor hospitalization- and mortality-related outcomes, important given increasing hepatic encephalopathy-related hospitalizations over time. The aim of this narrative review is to provide an overview of hospital- and mortality-related outcomes in patients with overt hepatic encephalopathy and the pharmacologic therapies that may improve these outcomes....
Source
#1Michael P. Curry (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 43
#2Steven L. Flamm (NU: Northwestern University)H-Index: 44
Last. Nezam H. Afdhal (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 94
view all 7 authors...
BACKGROUND: Direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) have varying potentials for drug-drug interactions (DDIs). OBJECTIVES: To (1) identify prevalence of potential DDI with glecaprevir-pibrentasvir (GLE-PIB) and sofosbuvir-velpatasvir (SOF-VEL) and (2) describe health care provider actions in response to pharmacist recommendations based on potential interactions with GLE-PIB or SOF-VEL, using 2 complementary data sources. METHODS: Possible interacting drugs were identif...
Source
#1Steven L. Flamm (NU: Northwestern University)H-Index: 44
#2Kimberly A. Brown (Ford Motor Company)H-Index: 21
Last. Sammy Saab (UCLA: University of California, Los Angeles)H-Index: 72
view all 9 authors...
Acute kidney injury in the setting of cirrhosis (hepatorenal syndrome-acute kidney injury [HRS-AKI]) is a severe and often fatal complication of end-stage liver disease. The goals of treatment are to reverse renal failure and prolong survival in critically ill patients. However, interventions have limited efficacy, and mortality rates remain high. In the US, the mainstay of pharmacologic therapy consists of the off-label use of vasoconstrictive agents in combination with plasma expanders, a stra...
Source
#1Monica M. Matsumoto (NU: Northwestern University)H-Index: 2
#2Samdeep K. Mouli (NU: Northwestern University)H-Index: 18
Last. Steven L. Flamm (NU: Northwestern University)H-Index: 44
view all 20 authors...
Purpose To evaluate hepatocellular carcinoma (HCC) treatment allocation, deviation from BCLC first-treatment recommendation, and outcomes following multidisciplinary, individualized approach. Methods Treatment-naive HCC discussed at multidisciplinary tumor board (MDT) between 2010 and 2013 were included to allow minimum 5 years of follow-up. MDT first-treatment recommendation (resection, transplant, ablation, transarterial radioembolization (Y90), transarterial chemoembolization, sorafenib, pall...
Source
#1Ahmed Gabr (NU: Northwestern University)H-Index: 17
#2Laura Kulik (NU: Northwestern University)H-Index: 67
Last. Riad Salem (NU: Northwestern University)H-Index: 95
view all 21 authors...
: Radioembolization (Y90) is used in hepatocellular carcinoma (HCC) as a bridging as well as downstaging liver directed therapy to curative liver transplantation. In this study we report long-term outcomes of liver transplantation (LT) for HCC patients bridged/downstaged by Y90. Patients undergoing LT following Y90 between 2004-2018 were included, with staging by United Network of Organ Sharing (UNOS) TNM at baseline pre-Y90 and pre-LT. Post-Y90 toxicities were recorded. Histopathological data o...
Source
#1Andrew C. Gordon (NU: Northwestern University)H-Index: 15
#2Aakash Gupta (NU: Northwestern University)H-Index: 2
Last. Robert J. Lewandowski (NU: Northwestern University)H-Index: 73
view all 18 authors...
PURPOSE To evaluate safety and efficacy of segmental yttrium-90 (Y90) radioembolization for hepatocellular carcinoma (HCC) after transjugular intrahepatic portosystemic shunt (TIPS) placement. The hypothesis was liver sparing segmental Y90 for HCC after TIPS would provide high antitumor response with a tolerable safety profile. MATERIALS AND METHODS This single-arm retrospective study included 39 patients (16 women, 23 men) with ages 49-81 years old who were treated with Y90. Child-Pugh A/B live...
Source
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.